Core Viewpoint - The company focuses on the research, development, production, and sales of POCT reagents and instruments, with a significant portion of its revenue derived from drug abuse testing and infectious disease testing, which together account for approximately 80% of total revenue [1] Group 1: Business Focus - The company's main products include drug abuse testing, infectious disease testing, reproductive health testing, tumor marker testing, and cardiac marker testing [1] - Approximately 75% of the company's revenue comes from overseas sales, indicating a strong international market presence [1] Group 2: Financial Outlook - The company anticipates a significant decline in operating revenue in 2025 due to multiple rounds of tariff policies from the U.S. government and cyclical fluctuations in the infectious disease testing market, particularly for respiratory and tropical diseases [1] - Increased R&D expenses and share-based payment costs are expected to put additional pressure on the company's performance [1] Group 3: Future Prospects - Despite the challenges, the company is confident in maintaining steady revenue growth in 2026, supported by the introduction of differentiated competitive products and the ongoing approval of product registration certificates [1] - Notable achievements include the FDA 510(k) approval for fentanyl testing (OTC) in October 2025 and the gradual approval of IVDR certificates, along with the registration of microfluidic fluorescent immuno POCT products in China, the EU, and Southeast Asia [1]